NYO3 Launches LPC Brain Innovation by Aker BioMarine

NYO3 Launches LPC Brain Innovation by Aker BioMarine

A New Era in Anti-Ageing Nutrition Unveiled at Vitafoods Asia 2025

As global attention continues to focus on brain health and longevity, the Vitafoods Asia 2025 exhibition in Bangkok provided a timely platform for a groundbreaking development in anti-ageing nutrition. This event, held from 17 to 19 September 2025, is recognized as one of the most influential gatherings in the nutraceutical and functional food sectors in Asia. Among the highlights was the debut of a revolutionary product designed to enhance cognitive resilience and improve nutrient absorption.

Norwegian premium dietary nutrition brand NYO3 returned for its second consecutive year at the event. Collaborating with Aker BioMarine, a leading krill oil company, NYO3 introduced its latest innovation: the NYO3 Lysophosphatidylcholines DHA Softgel. This product is part of the brand’s ‘Norway L3’ phospholipid innovation portfolio, which has attracted significant interest from industry professionals and potential partners.

According to a report by Grand View Research, the global marine phospholipid market is projected to exceed USD 500 million by 2030. In response to this growing demand, NYO3 has partnered with Aker BioMarine to launch the first LPC (Lysophosphatidylcholine) product developed and manufactured independently by a Norwegian brand. The NYO3 Lysophosphatidylcholines DHA Softgel is set to make its debut in China, a market with substantial demand for high-quality nutritional solutions. Aker BioMarine has officially certified this product as “The only certified LPC-based Brain Gold product in China,” highlighting its technological superiority and competitive edge.

The formulation of the NYO3 Lysophosphatidylcholines DHA Softgel includes the fourth-generation LYSOVETAS patented ingredient. This ingredient features Lysophosphatidylcholine (LPC), a phospholipid form of DHA that is scientifically recognized as the most effective form of DHA for brain absorption [Cui XY et al., Food Funct., 2020]. This innovation represents a major step forward in the field of brain health and cognitive support.

In addition to the Lysophosphatidylcholines DHA Softgel, NYO3 also revealed two other phospholipid-based anti-ageing innovations during the exhibition: the NYO3 Antarctic Supreme Phospholipids Krill Oil and the NYO3 Efficient Liver Metabolism. These products, together with the DHA Softgel, form the 'Norway L3: A New Era in Anti-Ageing Nutrition' portfolio. This collection aims to support brain, liver, and lipid health through advanced Norwegian science and technology.

The launch of these products marks a significant milestone in the evolution of anti-ageing nutrition. By combining scientific research with innovative formulations, NYO3 is setting new standards in the industry. As the demand for effective and sustainable health solutions continues to rise, the Norway L3 portfolio offers a promising pathway for consumers seeking to enhance their well-being and longevity.

With a strong presence in the Asian market and a commitment to quality and innovation, NYO3 is poised to make a lasting impact on the global nutraceutical landscape. The success of the NYO3 Lysophosphatidylcholines DHA Softgel and its related products underscores the brand’s dedication to advancing health and wellness through cutting-edge science.

Comments

Popular posts from this blog

Infinix HOT 60 Pro+ Sets GUINNESS WORLD RECORDS™ as the World’s Thinnest 3D Curved Display Smartphone

KakaoTalk Overhaul Adds ChatGPT, Message Editing

Fasoo Finalist in ‘Best AI Integration’ at 2025 A.I. Awards